

REMARKS

All of Applicants' pending claims (1-46) were subject to restriction and divided into seven groups. Applicants elect Group III and further elect Example 47, (R)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylic acid [2-[1,4']bipiperidinyl-1'-yl-2-oxo-1-(2-oxo-2,3-dihydro-benzooxazol-6-ylmethyl)-ethyl]-amide, as the species to advance prosecution. In this respect Applicants have without prejudice canceled claims directed to non-elected subject matter (claims 3-5, 32-36, 38 and 40-46). Original claims 2, 6-30 and 37 along with amended claims 1 and 31 remain pending.

Applicants' understanding is that the Examiner intends Group III to be directed to non-spirocyclic heteroarylsubstituted piperidines where $A=C$, $p=1$, $m=1$, $n=1$ and GEJ is A^* . In this respect, out of the three values provided for A in the original claims (where A is C, CH or N), the correct substitution in terms of valency for nonspirocyclic piperidinyl ring systems should be CH not C. Thus, Applicants have amended Group III such that $A = CH$ not C.


Pursuant to MPEP 809.04, Applicants reserve the right to reintroduce method of treatment claims which contain all the limitations of any elected composition claims (linking claims) that are deemed allowable and further reserve the right to file divisional applications on any non-elected subject matter.

CASE: CT2777A US - CIP [1]

In respect of the above, Applicants respectfully request the Examiner to enter said amendments and submit that the application is in condition for examination on the merits. The Commissioner is authorized to withdraw any fees from Deposit Account 19-3880.

Date: December 21, 2005

Respectfully submitted,



Shah R. Makujina
Agent for Applicants
Reg. No. 41,174
Phone: (203) 677-7268

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000